Karyopharm Therapeutics reported $6.11M in Interest Expense on Debt for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US USD 66M 75M
Amgen AMGN:US USD 415M 47M
Biocryst Pharmaceuticals BCRX:US USD 24.78M 753K
Bristol Myers Squibb BMY:US USD 299M 14M
Eli Lilly And LLY:US USD 81.5M 300K
Karyopharm Therapeutics KPTI:US USD 6.11M 199K
Merk MRK:US USD 244M 4M
Nektar Therapeutics NKTR:US USD 6.95M 275K
Novartis NOVN:VX USD 215M 13M
Pfizer PFE:US USD 313M 2M
Regeneron Pharmaceuticals REGN:US USD 15.3M 2.2M
Roche Holding ROG:VX 256M 90M
Tg Therapeutics TGTX:US USD 1.65M 1.37M